<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02375295</url>
  </required_header>
  <id_info>
    <org_study_id>H13-02514</org_study_id>
    <nct_id>NCT02375295</nct_id>
  </id_info>
  <brief_title>Struvite Stones Antibiotic Study</brief_title>
  <official_title>A Prospective Randomized Trial of 2 Weeks vs 3 Months of Antibiotics Post Percutaneous Nephrolithotomy for the Prevention of Infection-Related Kidney Stones</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this research is to determine an effective antibiotic regimen following definitive
      surgical therapy of kidney stones caused by bacterial infection (struvite stones).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Struvite stones or infection stones are a subset of kidney stones that are related to
      bacterial infection. They only make up 15% of all kidney stones, but account for a much
      higher percentage of mortality (up to 67%) compared to other stones—due to the infectious
      component. Treatment is to ensure 100% eradication of the stone with surgery followed by
      antibiotics to eliminate the infection. Failure to eliminate the bacteria results in the
      stone growing back quickly. It is unknown how long antibiotics should be administered
      immediately after surgery—some urologists give 2-4 weeks while others give 2-3 months. We
      seek to randomize patients to receive 2 weeks of antibiotics or 3 months of antibiotics after
      surgery to remove all the kidney stones. We will see patients at 3, 6, and 12 months with
      x-rays and to test their urine for bacterial infections. This is a multi-centre study with
      participating 12 sites across North America.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>any recurrent kidney stones</measure>
    <time_frame>6 months</time_frame>
    <description>Radiologic recurrence of calculi in the location of original treatment at or before 6 months following definitive surgical therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>UTI</measure>
    <time_frame>1 year</time_frame>
    <description>Positive urine cultures at any point within 1 year from surgical therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treated site stone recurrence rates</measure>
    <time_frame>1 year</time_frame>
    <description>Radiologic recurrence of calculi in the location of original treatment at or before 12 months following definitive surgical therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clostridiuum difficile colitis</measure>
    <time_frame>1 year</time_frame>
    <description>Antibiotic related complications such as Clostridiuum difficile colitis infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ER visit</measure>
    <time_frame>POD1</time_frame>
    <description>In hospital sepsis and febrile episodes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission for sepsis.</measure>
    <time_frame>3 months</time_frame>
    <description>Readmission for sepsis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission for renal colic</measure>
    <time_frame>3 months</time_frame>
    <description>Readmission for renal colic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity or mortality related to sepsis or renal failure</measure>
    <time_frame>3 months</time_frame>
    <description>Morbidity or mortality related to sepsis or renal failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repeat surgical procedures for stone recurrence</measure>
    <time_frame>3 months</time_frame>
    <description>Repeat surgical procedures for stone recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ancillary procedures for stones such as ureteric stenting and nephrostomy tubes</measure>
    <time_frame>3 months</time_frame>
    <description>Ancillary procedures for stones such as ureteric stenting and nephrostomy tubes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Kidney Stones</condition>
  <arm_group>
    <arm_group_label>Arm A: 2 weeks Abx post PCNL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral antibiotics: ciprofloxacin, cotrimoxazole-trimethoprim, or macrodantin are administered for 2 weeks at full dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: 12 weeks/3 months Abx post PCNL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral antibiotics: ciprofloxacin, cotrimoxazole-trimethoprim, or macrodantin are administered for 2 weeks at full dose followed by a suppressive dose for another 10 weeks (total = 12 weeks or 3 months).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ciprofloxacin, cotrimoxazole-trimethoprim, macrodantin</intervention_name>
    <description>Approved antibiotics used routinely will be given at the physician's discretion with the patient: ciprofloxacin, cotrimoxazole-trimethoprim, or macrodantin</description>
    <arm_group_label>Arm A: 2 weeks Abx post PCNL</arm_group_label>
    <arm_group_label>Arm B: 12 weeks/3 months Abx post PCNL</arm_group_label>
    <other_name>Keflex, Macrobid, co-trimoxazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or Female.

          2. No age restriction.

          3. Diagnosed with an infection related stone.

          4. Medically fit for definitive surgical management of stone.

          5. Life expectancy greater than one year.

          6. Stone free after definitive surgical therapy defined as fragments less than 3mm.

        Exclusion Criteria:

          1. Patients with medical comorbidities preventing them from definitive surgical therapy.

          2. Patients with persistent stone burden following definitive surgical therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ben Chew, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olga Arsovska</last_name>
    <phone>6048754111</phone>
    <phone_ext>62421</phone_ext>
    <email>olga.arsovska@ubc.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic - Scottsdale/Phoenix, AZ</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchell Humphreys, MD</last_name>
      <email>Humphreys.Mitchell@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roger Sur, MD</last_name>
      <email>rlsur@mail.ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Matlaga</last_name>
      <email>bmatlag1@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harvard University - Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114-3117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Eisner, MD</last_name>
      <email>BEISNER@PARTNERS.ORG</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester, MN</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Krambeck, MD</last_name>
      <email>krambeck.amy@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dartmouth University</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756-0001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vernon Pais, MD</last_name>
      <email>Vernon.M.Pais.Jr@hitchcock.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ojas Shah, MD</last_name>
      <email>Ojas.Shah@nyumc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Lipkin, MD</last_name>
      <email>michael.lipkin@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Athens</city>
        <state>Ohio</state>
        <zip>45701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bodo Knudsen, MD</last_name>
      <email>Bodo.Knudsen@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Janet McGarr</last_name>
      <email>Janet.Mcgarr@osumc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manoj Monga, MD</last_name>
      <email>mongam@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Miller, MD</last_name>
      <email>nicole.miller@Vanderbilt.Edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Stone Centre, VGH/UBC</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Arsovska</last_name>
      <phone>604 875 4111</phone>
      <phone_ext>62421</phone_ext>
      <email>olga.arsovska@ubc.ca</email>
    </contact>
    <investigator>
      <last_name>Ben Chew, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dirk Lange, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ryan Flannigan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ryan Paterson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elspeth McDougall, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2015</study_first_submitted>
  <study_first_submitted_qc>February 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2015</study_first_posted>
  <last_update_submitted>January 2, 2018</last_update_submitted>
  <last_update_submitted_qc>January 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Ben Chew</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>struvite</keyword>
  <keyword>infection</keyword>
  <keyword>stones</keyword>
  <keyword>calculi</keyword>
  <keyword>antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calculi</mesh_term>
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Nitrofurantoin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

